Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troriluzole for obsessive compulsive disorder
NCT04708834Phase 3Terminated
- Sponsor
- Biohaven Ltd.
- Start
- Mar 2021
- Primary completion
- Feb 2026
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of troriluzole in obsessive compulsive disorder (OCD), sponsored by Biohaven Ltd. Primary endpoint: Long term safety and tolerability at 240 weeks. Started Mar 2021; status: terminated.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT04708834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708834.